Jamie Stiff

Mr. Stiff joined Genesys Capital in 2002 and became Partner at the firm in 2007. During his career at Genesys, he has been responsible for investments in several early-stage portfolio companies that cross a multitude of clinical disciplines and technology areas. Current board affiliations include Feldan Therapeutics, Giiant Pharma Inc., and Veralox Therapeutics, Inc. Past board affiliations include Allostera Pharma, EBT Medical, Fairhaven Pharmaceuticals (Acquired by Liminal BioSciences Inc. NASDAQ:LMNL), gIcare Pharma, Inversago Pharma (Acquired by Novo Nordisk) Interface Biologics, Matregen, Naurex (acquired by Allergan NYSE:AGN), NeurAxon, StemPath, Therapeutic Monitoring Systems and Zelos Therapeutics. Mr. Stiff also volunteers as a board member for BioteCanada, and as an advisor to the Ontario Genomics Institute (OGI), the Centre for Commercialization of Regenerative Medicine (CCRM) and Medicine by Design and as an associate with the Creative Destruction Lab (CDL).

‍

Prior to joining Genesys, Mr. Stiff worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics field. This experience, combined with an academic background in biology, has provided significant technical knowledge of many areas of life sciences. Mr. Stiff completed a Bachelor of Science (Honours) from Queen’s University and an MBA from the Rotman School of Management.